カテゴリー： Allied Market Research, 中南米, 医療/バイオ

性的欲求低下障害（HSDD）治療の中南米市場2020–2027：治療種類別（ブスピロン、ブプロピオン、ブレメラノチド、フリバンセリン）、販売チャネル別

【英語タイトル】LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market by Treatment Type (Buspirone, Bupropion, Bremelanotide, and Flibanserin), Sales Channel (Hospitals, Clinics, and Online Retailers): Regional Opportunity Analysis and Industry Forecast, 2020–2027

Allied Market Researchが出版した調査資料（AMR20DC53）・商品コード：AMR20DC53
・発行会社（調査会社）：Allied Market Research
・発行日：2020年10月
・ページ数：150
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：中南米
・産業分野：生命科学
◆販売価格オプション（消費税別）
Single UserUSD4,649 ⇒換算￥483,496見積依頼/購入/質問フォーム
5 UserUSD5,105 ⇒換算￥530,920見積依頼/購入/質問フォーム
Enterprise UserUSD7,119 ⇒換算￥740,376見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
本調査レポートでは、性的欲求低下障害（HSDD）治療の中南米市場について調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、治療種類別分析、販売チャネル別分析、用途別分析、国別分析、企業情報などの項目を掲載しています。
【レポートの概要】

The LATAM women hypoactive sexual desire disorder treatment market accounted for $967 million in 2019, and is expected to reach $1,275 million by 2027, registering a CAGR of 6.1% from 2020 to 2027.
Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction that occurs in adult women globally, manifested by lack of sex interest for a period of six months or more, owing to personal distress or fluctuating sex hormones during menstrual cycle. Hypoactive sexual desire disorder is also known as female sexual interest/arousal disorder. HSDD is currently on the rise in adult women population, which causes low self-confidence and less connection with partners.

Hypoactive sexual desire disorder is classified into primary, secondary, acquired and generalized, or situational. Accurate diagnosis of symptoms of HSDD is very critical to finalize the treatment procedure, which is either psychotherapy or pharmacotherapy. Pharmacotherapy comprises buspirone and bupropion off label non hormonal treatment for HSDD in women suffering from low libido associated with anxiety and depression. Moreover, cognitive behavior therapy is suggested to patients showing a positive response to counseling sessions with a sex therapist.
In addition, Flibanserin is currently the only drug approved by the US FDA (Food & Drug Administration) for treating HSDD in premenopausal women, owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.

The LATAM women hypoactive sexual desire disorder (HSDD) treatment market is expected to register substantial growth in the future, owing to rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue and rise in use of medicines, which induces the state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, rise in number of surgical procedures, which leads to sexual dysfunction, are expected to boost the growth of LATAM women hypoactive sexual desire disorder treatment market during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in the coming years. Hence, the presence of pipeline drugs offers a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.

The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone, bupropion, bremelanotide, and flibanserin. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, it is classified into Brazil, Argentina, Chile, Colombia, and rest of the LATAM.
The key players operating in the LATAM women hypoactive sexual desire disorder treatment market include Aurobindo Pharma, Bristol-Myers Squibb Company, Glaxo Smith Kline (GSK), Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceuticals, Novartis (Sandoz), Sun Pharmaceutical Industries Ltd., and Cadila Healthcare (Zydus). Product launch and acquisition were the most common strategies adopted by the key players, which has led to expansion of their product offerings.

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global LATAM women hypoactive sexual desire disorder treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments
• By Treatment Type
o Buspirone
o Bupropion
o Bremelanotide
o Flibanserin

• By Sales Channel
o Hospitals
o Clinics
o Online Retailers

• By Country
 Brazil
 Argentina
 Chile
 Colombia
 Rest of LATAM

• List of key players profiled in the report:
• Aurobindo Pharma
• Bristol-Myers Squibb Company
• GlaxoSmithKline Plc
• Mylan N.V.
• Novartis AG
• Palatin Technologies, Inc.
• Sprout Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Zydus Cadila

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Shanghai Fosun Pharmaceutical Co., Ltd.
• Amneal Pharmaceuticals
• Allergan plc

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top Winning Strategies
3.2.2.Top investment pockets

3.3.Key forces shaping LATAM women hypoactive sexual desire disorder treatment industry/market
3.4.Top player positioning, 2019
3.5.Annual Spending, 2019
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Surge in prevalence of lifestyle ailments
3.6.1.2.Rise in use of medicines that induce hypoactive sexual desire disorder
3.6.1.3.Rise in number of surgical procedures leading to sexual dysfunction

3.6.2.Restraint

3.6.2.1.Lack in awareness related to hypoactive sexual desire disorder

3.6.3.Opportunity

3.6.3.1.Presence of strong pipeline products

3.7.Impact Analysis
3.8.COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
3.9.Cognitive Behavior Therapy

3.9.1.Key market trends, growth factors, and opportunities
3.9.2.Market analysis, by country

CHAPTER 4:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Buspirone

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market analysis, by country

4.3.Bupropion

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market analysis, by country

4.4.Bremelanotide

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market analysis, by country

4.5.Flibanserin

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market analysis, by country

CHAPTER 5:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospitals

5.2.1.Market analysis, by country

5.3.Clinics

5.3.1.Market analysis, by country

5.4.Online Retailers

5.4.1.Market analysis, by country

CHAPTER 6:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY

6.1.Overview

6.1.1.Market size and forecast, by country

6.2.Brazil

6.2.1.Key market trends and growth opportunities
6.2.2.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.2.3.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.3.Argentina

6.3.1.Key market trends and growth opportunities
6.3.2.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.3.3.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.4.Chile

6.4.1.Key market trends and growth opportunities
6.4.2.Chile hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.4.3.Chile hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.5.Colombia

6.5.1.Key market trends and growth opportunities
6.5.2.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.5.3.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

6.6.Rest of LATAM

6.6.1.Key market trends and growth opportunities
6.6.2.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.6.3.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by sales channel

CHAPTER 7:COMPANY PROFILES

7.1.AUROBINDO PHARMA

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance.

7.2.BRISTOL-MYERS SQUIBB COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product Portfolio
7.2.5.Business performance

7.3.GLAXOSMITHKLINE PLC (GSK)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.

7.4.MYLAN N.V.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance

7.5.NOVARTIS INTERNATIONAL AG

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.PALATIN TECHNOLOGIES, INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.6.6.Key strategic moves and developments

7.7.SPROUT PHARMACEUTICALS, INC.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments

7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance

7.10.ZYDUS CADILA

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.

LIST OF TABLES

TABLE 01.ANNUAL SPENDING ON WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT, BY COUNTRY, 2019 (US$)
TABLE 02.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 03.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 (NUMBER OF SESSIONS)
TABLE 04.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 05.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 06.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 07.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 08.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 09.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 10.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 11.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 12.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 13.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 14.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 15.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 16.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 17.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 18.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 20.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 22.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 23.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 24.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 25.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 26.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 27.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 28.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 29.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 30.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 31.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 32.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 33.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 34.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 35.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 36.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 37.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 38.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 39.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 40.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 41.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 42.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 43.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 44.AUROBINDO: COMPANY SNAPSHOT
TABLE 45.AUROBINDO: PRODUCT PORTFOLIO
TABLE 46.BMS: COMPANY SNAPSHOT
TABLE 47.BMS: PRODUCT PORTFOLIO
TABLE 48.GSK: COMPANY SNAPSHOT
TABLE 49.GSK: OPERATING SEGMENTS
TABLE 50.GSK: PRODUCT PORTFOLIO
TABLE 51.MYLAN: COMPANY SNAPSHOT
TABLE 52.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 53.MYLAN: PRODUCT PORTFOLIO
TABLE 54.NOVARTIS: COMPANY SNAPSHOT
TABLE 55.NOVARTIS: OPERATING SEGMENTS
TABLE 56.NOVARTIS: PRODUCT PORTFOLIO
TABLE 57.PALATIN: COMPANY SNAPSHOT
TABLE 58.PALATIN: PRODUCT PORTFOLIO
TABLE 59.SPROUT: COMPANY SNAPSHOT
TABLE 60.SPROUT: OPERATING SEGMENTS
TABLE 61.SPROUT: PRODUCT PORTFOLIO
TABLE 62.SPROUT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.SUN PHARMA: COMPANY SNAPSHOT
TABLE 64.SUN PHARMA: OPERATING SEGMENTS
TABLE 65.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 66.TEVA: COMPANY SNAPSHOT
TABLE 67.TEVA: OPERATING SEGMENTS
TABLE 68.TEVA: PRODUCT PORTFOLIO
TABLE 69.ZYDUS: COMPANY SNAPSHOT
TABLE 70.ZYDUS: OPERATING SEGMENTS
TABLE 71.ZYDUS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET SEGMENTATION:
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 04.LOW BARGAINING POWER OF BUYERS
FIGURE 05.LOW THREAT OF SUBSTITUTES
FIGURE 06.HIGH INTENSITY OF RIVALRY
FIGURE 07.MODERATE THREAT OF NEW ENTRANT
FIGURE 08.TOP PLAYER POSITIONING, 2019
FIGURE 09.IMPACT ANALYSIS, LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET
FIGURE 10.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 11.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 12.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 13.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 14.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 19.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 21.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 22.PALATIN: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 25.SUN PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2020 (%)
FIGURE 26.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)



★調査レポート[性的欲求低下障害（HSDD）治療の中南米市場2020–2027：治療種類別（ブスピロン、ブプロピオン、ブレメラノチド、フリバンセリン）、販売チャネル別] (コード：AMR20DC53)販売に関する免責事項を必ずご確認ください。
★調査レポート[性的欲求低下障害（HSDD）治療の中南米市場2020–2027：治療種類別（ブスピロン、ブプロピオン、ブレメラノチド、フリバンセリン）、販売チャネル別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • デジタル治療のアメリカ市場2020–2027：用途別（糖尿病、肥満、心血管疾患（CVD）、中枢神経系（CNS）疾患、呼吸器疾患、禁煙、胃腸障害（GID）、その他）、製品別、販売チャネル別
    AMR20OC075 / Allied Market Research / 2020年8月 / 本調査レポートでは、デジタル治療のアメリカ市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、用途別分析、製品別分析、販売チャネル別分析、競争状況、企業情報など、以下の構成でまとめております。...The U.S. digital therapeutics market size was valued at $1.16 billion in 2019 and is expected to reach $5.08 billion by 2027 with a CAGR of 19.2% during the forecast period. Digital therapeutics provides evidence-based therapeutic interventions to patients. It is driven by software programs and devices to prevent, manage, or treat a medical condition. Digital therapeutics software application can be used independently or in combination with devices, medications, or any other therapies to provide patient care and health outcomes. These products incorporate advanced technology, best practices regarding the design, usability, clinical validation, and data security. These products are reviewed...
  • 関節リウマチ治療薬の世界市場2020–2027：医薬品クラス別（疾患修飾性抗リウマチ薬、非ステロイド性抗炎症薬、コルチコステロイド、尿酸薬、その他）、投与経路別、販売チャネル別
    AMR20DC01 / Allied Market Research / 2020年10月 / 本調査レポートでは、関節リウマチ治療薬の世界市場について調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、医薬品クラス別（疾患修飾性抗リウマチ薬、非ステロイド性抗炎症薬、コルチコステロイド、尿酸薬）分析、投与経路別（経口、非経口）分析、販売チャネル別（処方薬、店頭薬）分析、地域別分析、企業情報などの項目を掲載しています。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・関節リウマチ治療薬の世界市場規模：医薬品クラス別（疾患修飾性抗リウマチ薬、非ステロイド性抗炎症薬、コルチコステロイド、尿酸薬） ・関節リウマチ治療薬の世界市場規模：投与経路別（経口、非経口） ・関節リウマチ治療薬の世界市場規模：販売チャネル別（処方薬、店頭薬） ・関節リウマチ治療薬の世界市場規模：地域別 ・企業情報...The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Rheumatoid arthritis is an autoimmune disease that majorly affects joints along with articular tissues and extra-articular organs. It is considered as a systemic disease, as it affects the cardiac and respiratory system. In addition, this medical condition is often progressive, and results in stiffness, pain, redness, and swelling of joints. Moreover, as no permanent cure is available for rheumatoid arthritis, the aim of the treatment is to reduce pain,...
  • ヘッドアップディスプレイの世界市場2020–2027：種類別（フロントガラスベース、コンバイナーベース）、技術別、エンドユーザー別、販売チャネル別
    AMR20OC054 / Allied Market Research / 2020年8月 / 本調査レポートでは、ヘッドアップディスプレイの世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、種類別分析（フロントガラスベース、コンバイナーベース）、技術別分析（従来型、ARベース）、エンドユーザー別分析（航空、自動車）、販売チャネル別分析（OEM、アフターマーケット）、地域別分析情報、競争状況、企業情報など、以下の構成でまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・ヘッドアップディスプレイの世界市場規模：種類別（フロントガラスベース、コンバイナーベース） ・ヘッドアップディスプレイの世界市場規模：技術別（従来型、ARベース） ・ヘッドアップディスプレイの世界市場規模：エンドユーザー別（航空、自動車） ・ヘッドアップディスプレイの世界市場規模：販売チャネル別（OEM、アフターマーケット） ・ヘッドアップディスプレイの世界市場規模：地域別 ・競争状況...The global head-up display market was valued at $6.0 billion in 2019, and is projected to reach $19.1 billion by 2027, registering a CAGR of 20.1% from 2020 to 2027. A head-up display is a semi-transparent screen played above cockpit in aircrafts or infotainment dashboard in cars in the direction of the forward view that displays the cars’ or flights’ parameters, allowing the users’ to keep focus forward. Head-up displays are smart, safe, and revolutionizing the safety features of vehicles. Enhanced safety offered by the head-up display systems majorly drives the growth of the market, as it assists to drive...
  • ストリーミングデバイスの世界市場2020–2027：コンポーネント別（ハードウェア、ソフトウェア）、販売チャネル別、価格帯別、用途別、最終用途別
    AMR20OC055 / Allied Market Research / 2020年8月 / 本調査レポートでは、ストリーミングデバイスの世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、コンポーネント別分析（ハードウェア、ソフトウェア）、販売チャネル別分析（オンライン、オフライン）、価格帯別分析（低価格、中価格、高価格）、用途別分析（テレビ、ゲーム、その他）、最終用途別分析（家庭用、商業用）、地域別分析情報、競争状況、企業情報など、以下の構成でまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・ストリーミングデバイスの世界市場規模：コンポーネント別（ハードウェア、ソフトウェア） ・ストリーミングデバイスの世界市場規模：販売チャネル別（オンライン、オフライン） ・ストリーミングデバイスの世界市場規模：価格帯別（低価格、中価格、高価格） ・ストリーミングデバイスの世界市場規模：用途別（テレビ、ゲーム、その他） ・ストリーミングデバイスの世界市場規模：最終用途別（家庭用、商業用） ・ストリーミングデバイスの世界市場規模：地域別...The global streaming devices market size was valued at $8.00 billion in 2018 and is estimated to reach $18.97 billion by 2027, growing at CAGR of 13.2% from 2019 to 2027. Streaming is a technology which is used to deliver content to various devices such as computers, laptops, tablets and mobile devices through the internet. Streaming transmits data by usually two means that is audio and video. In addition, it helps in connecting television or home theater to the Internet and allows to stream video and music from online services. By using streaming platforms, user can view a video and...
  • サージカルマスクのインド市場2020–2027：製品別（基本サージカルマスク、防曇サージカルマスク、流体/防滴サージカルマスク、N95マスク）、流通チャネル別、販売チャネル別
    AMR20OC077 / Allied Market Research / 2020年8月 / 本調査レポートでは、サージカルマスクのインド市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、製品別分析、流通チャネル別分析、販売チャネル別分析、競争状況、企業情報など、以下の構成でまとめております。...Surgical masks are the U.S. FDA regulated masks that are considered to be fluid resistant and protect the wearer against splashes or spray of bodily or hazardous fluids and large droplets. The medical staff usually prefer these masks in an operative or procedural hospital setting. These masks protect the wearer by creating a barrier to the microorganisms and thereby preventing cross-contamination. During disease outbreaks such as COVID-19 pandemic, health officials recommend the public to wear surgical masks in order to control the spread of the disease. The India surgical mask market was valued at $71.73 million in 2019, and is...
  • ナルコレプシー治療薬の世界市場：疾患種類別、治療種類別
    AMR9NV071 / Allied Market Research / 2019年7月 / 当調査レポートでは、ナルコレプシー治療薬の世界市場について調査・分析し、市場概要、病気種類別（昼間極度眠気、カタプレニア、その他）分析、治療種類別（中枢神経系刺激薬、三環系抗うつ薬、オキシケイ酸ナトリウム、選択的セロトニン再取り込み阻害薬など）分析、地域別分析、競争状況、企業動向など含め、以下の構成でお届け致します。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・ナルコレプシー治療薬の世界市場：病気種類別（昼間極度眠気、カタプレニア、その他） ・ナルコレプシー治療薬の世界市場：治療種類別（中枢神経系刺激薬、三環系抗うつ薬、オキシケイ酸ナトリウム、選択的セロトニン再取り込み阻害薬など） ・ナルコレプシー治療薬の世界市場：地域別 ・競争状況 ・企業動向 ...Narcolepsy is characterized by several symptoms that include cataplexy, excessive daytime sleepiness, hallucinations, and sleep paralysis. In addition, patients suffering from narcolepsy experience automatic behaviors such as eating, walking, or driving, in a dazed manner. Symptoms differ from patient to patient, and are diagnosed between the ages of 7 and 25. The global narcolepsy drugs market accounted for around $2,429 million in 2018, and is expected to reach $5,360 million by 2026, registering a CAGR of 10.3% from 2019 to 2026. Although narcolepsy is a rare and underdiagnosed chronic condition, many cases have been reported of the people affected by...
  • 世界の脱毛症治療市場2020-2027：疾患種類別（円形脱毛症、瘢痕性脱毛症、牽引性脱毛症、全頭脱毛症、全身性脱毛症、男性型脱毛症、その他）、エンドユーザー別、販売チャネル別、性別、地域別
    BZW20OC006 / Bizwit Research & Consulting / 2020年9月15日 / 本市場調査資料では、脱毛症治療の世界市場を広く調査・分析し、エグゼクティブサマリー、市場定義・範囲、市場動向、市場分析、疾患種類別（円形脱毛症治療、瘢痕性脱毛症治療、牽引性脱毛症治療、全頭脱毛症治療、全身性脱毛症治療）分析、エンドユーザー別（在宅医療、皮膚科クリニック）分析、販売チャネル別（処方箋、OTC）分析、性別（男性、女性）分析、地域別分析、競争状況、調査プロセスなど、以下の構成でまとめております。 ・エグゼクティブサマリー ・市場定義・範囲 ・市場動向 ・市場分析 ・脱毛症治療の世界市場規模：疾患種類別（円形脱毛症治療、瘢痕性脱毛症治療、牽引性脱毛症治療、全頭脱毛症治療、全身性脱毛症治療） ・脱毛症治療の世界市場規模：エンドユーザー別（在宅医療、皮膚科クリニック） ・脱毛症治療の世界市場規模：販売チャネル別（処方箋、OTC） ・脱毛症治療の世界市場規模：性別（男性、女性） ・脱毛症治療の世界市場規模：地域別...Global Alopecia Treatment Market is valued approximately at USD 2.6 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 9.5 % over the forecast period 2020-2027. The Alopecia, also called baldness or hair loss, refers to hair removal from the head or body part. The disorder may appear in both male and female and in any age. To be precise, there are five main forms of alopecia, such as alopecia areata, androgenic alopecia, cicatricial alopecia, alopecia totalis and telogen effluvium. Alopecia areata is an autoimmune disease that affects the hair follicles and causes...
  • 既製服の世界市場2021–2027：製品別（インナー、アウター）、用途別、繊維種類別、年齢別、販売チャネル別
    AMR20SP070 / Allied Market Research / 2020年7月 / 本調査レポートでは既製服の世界市場について詳細に調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、製品別（アウター、インナー）分析、用途別（フォーマルウェア、スポーツウェア、カジュアルウェアー、安全服、その他）分析、繊維種類別（ニット、織り、不織）分析、年齢別（高齢、成人、子供、幼児）分析、流通チャンネル別（スーパーマーケット/ハイパーマーケット、独立小売店、専門店、電子商取引、その他）分析、地域別分析、企業情報など、今後の市場展望をまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・既製服の世界市場規模：製品別（アウター、インナー） ・既製服の世界市場規模：用途別（フォーマルウェア、スポーツウェア、カジュアルウェアー、安全服、その他） ・既製服の世界市場規模：繊維種類別（ニット、織り、不織） ・既製服の世界市場規模：年齢別（高齢、成人、子供、幼児） ・既製服の世界市場規模：流通チャンネル別（スーパーマーケット/ハイパーマーケット、独立小売店、専門店、電子商取引、その他） ・既製服の世界市場規模：地域別...Readymade garments are mass produced apparel, which are made from different fabric and yarn. These are finished products and are made according to different standard sizes. The readymade garment industry witnessed significant growth over the decade, as consumer income has grown and their affinity toward fashion has increased. Until the 21st century, Europe was the largest export of readymade garments, but from the early 2000s the production of readymade garments shifted to emerging countries such as India, Vietnam, Bangladesh, and China. This was done to reduce labor cost in production and make opportunities for jobs in this region. The growth...
  • スキンケア商品のバングラデシュ市場2021–2027：種類別（クリーム、ローション、その他）、性別、年齢別、販売チャネル別
    AMR20SP012 / Allied Market Research / 2020年7月 / ...Skin care is the practice of improving skin integrity, enhancing its appearance, and relieving skin conditions by using skin care products. Skin care products are manufactured using chemical compounds, medicinal herbs, or natural ingredients. They are sold in various forms, which include creams, lotions, serum, and face mask, among others. According to AMR, the Bangladesh skin care products market size was valued at $1.16 billion in 2020, and is expected to garner $2.12 billion by 2027, registering a CAGR of 8.1% from 2021 to 2027. The skin care products market exhibits an incremental revenue opportunity of $960 million from 2020...
  • ハーブ栄養補助食品の世界市場2021–2027：製品種類別（生姜、ニンニク、ターメリック、アロエベラ、緑茶、その他）、性質別、形態別、販売チャネル別
    AMR20OC034 / Allied Market Research / 2020年8月 / 本調査レポートでは、ハーブ栄養補助食品の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場動向、製品種類別分析（生姜、ニンニク、ターメリック、アロエベラ、緑茶、その他）、性質別分析（従来型、有機型）、形態別分析（粉末、液体、カプセル・錠剤、その他）、販売チャネル別分析（薬局、オンラインストア、スーパーマーケット/ハイパーマーケット、その他）、地域別分析情報、競争状況、企業情報など、以下の構成でまとめております。 ・イントロダクション ・エグゼクティブサマリー ・市場動向 ・ハーブ栄養補助食品の世界市場規模：製品種類別（生姜、ニンニク、ターメリック、アロエベラ、緑茶、その他） ・ハーブ栄養補助食品の世界市場規模：性質別（従来型、有機型） ・ハーブ栄養補助食品の世界市場規模：形態別（粉末、液体、カプセル・錠剤、その他） ・ハーブ栄養補助食品の世界市場規模：販売チャネル別（薬局、オンラインストア、スーパーマーケット/ハイパーマーケット、その他） ・ハーブ栄養補助食品の世界市場規模：地域別 ・競争状況...The global herbal nutraceuticals market was valued at $28,329.7 million in 2019, and is projected to reach $48,446.5 million by 2027, registering a CAGR of 7.55% from 2021 to 2027. Herbal nutraceuticals are obtained from natural sources with no added chemicals or toxins. These products are highly effective, safer, and more tolerable as compared to conventional products available in the market. Some of the common herbal nutraceuticals available in the market are aloe vera, garlic, ginger, green tea, and turmeric. Moreover, these herbal nutraceuticals are easily available in the market through various distribution channels including online stores, supermarkets/hypermarket, online stores,...

    • ◆H&Iグローバルリサーチのお客様（例）◆